PDF(Pubmed)
Abstract：
Background Acute gastroenteritis (AGE) is a major health concern in pediatric populations because of its associated vomiting, which worsens dehydration and the severity of illness. Objective The purpose of the research was to compare the relative effectiveness of oral ondansetron in treating AGE in children\'s vomiting when compared to oral domperidone and oral metoclopramide. Methodology A clinical investigation involving 120 pediatric patients diagnosed with AGE was conducted in Pakistan from November 2022 to April 2023 using a single-blind randomized design and convenience sampling. The participants received oral suspensions of ondansetron, metoclopramide, and domperidone, with doses of 0.15 mg/kg, 0.1-0.2 mg/kg, and 0.5 mg/kg, respectively, adjusted according to their body weight. The outcome in different groups was analyzed using the Statistical Package for the Social Sciences (SPSS) (version 20.0; IBM SPSS Statistics for Windows, Armonk, NY). Results At six hours, vomiting cessation rates were 80.0% for ondansetron (n=32), 72.5% for domperidone (n=29), and 67.5% for metoclopramide (n=27; p=0.29). By 24 hours, ondansetron exhibited significantly higher efficacy (92.5%; n=37) compared to domperidone (82.5%; n=33) and metoclopramide (77.5%; n=31; p=0.03). Adverse effects were minimal and comparable across groups. Conclusion Oral ondansetron demonstrated superior efficacy in managing AGE-related vomiting in children within 24 hours compared to metoclopramide and domperidone.
摘要：
背景急性胃肠炎（AGE）是儿科人群的主要健康问题，因为它与呕吐相关，这加剧了脱水和疾病的严重程度。目的比较口服昂丹司琼与口服多潘立酮和口服甲氧氯普胺治疗儿童呕吐的相对有效性。方法2022年11月至2023年4月，使用单盲随机设计和便利抽样，在巴基斯坦进行了一项涉及120名诊断为AGE的儿科患者的临床调查。参与者接受口服昂丹司琼悬浮液，甲氧氯普胺,还有多潘立酮,剂量为0.15mg/kg，0.1-0.2mg/kg,和0.5mg/kg，分别,根据他们的体重调整。使用社会科学统计软件包（SPSS）（20.0版；IBMSPSSStatisticsforWindows，Armonk,NY).结果六小时后,昂丹司琼(n=32)的呕吐停止率为80.0%，多潘立酮72.5%(n=29)，甲氧氯普胺为67.5%（n=27；p=0.29）。到24小时,昂丹司琼的疗效（92.5％；n=37）明显高于多潘立酮（82.5％；n=33）和甲氧氯普胺（77.5％；n=31；p=0.03）。不良反应很小，各组之间具有可比性。结论与甲氧氯普胺和多潘立酮相比，口服昂丹司琼在24小时内治疗儿童AGE相关性呕吐具有更好的疗效。
